Drug Profile


Alternative Names: PRS 375; PRS-211,375

Latest Information Update: 28 Jul 2009

Price : $50

At a glance

  • Originator Pharmos Corporation
  • Class Analgesics
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neuropathic pain; Pain

Most Recent Events

  • 10 Sep 2007 Discontinued - Phase-II for Pain in United Kingdom (IV)
  • 10 Sep 2007 Discontinued - Phase-I for Pain in Germany (IV)
  • 10 Sep 2007 Discontinued - Preclinical for Neuropathic pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top